Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Possible chinese partner?

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Jan 04, 2022 9:40am

119 Views

Post# 34281177

RE:RE:RE:RE:RE:RE:Possible chinese partner?

Is this is in person or via web?

LouisW wrote: Paul will attend the forum per the information on his Linkedin. I think he may bring some good news for investors.

ACCESS CHINA Biotech Forum is one of the largest corporate access events in China. It provides opportunities for business development, licensing deals, or commercial collaborations to global biopharmas. In the past event, more than 300 global companies that focus on oncology, cardiology, ophthalmology, orthopedics, pediatrics, and gastroenterology areas have participated to enter or expand their products in the Chinese market. For more information, please visit